Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.67 |
| ▸ | EGFR | P00533 | 13/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711467 | 0.91 | BRAF (0.54) | BRAFEGFRABL1BCRMAP3K7 | |
| SCHEMBL13708173 | 0.85 | BRAF (0.76) | BRAFEGFRABL1 | |
| SCHEMBL13708167 | 0.85 | ATM (0.69) | BRAFEGFRABL1MAP3K7MAP4K2 | |
| SCHEMBL13878777 | 0.82 | BRAF (0.66) | BRAFEGFRHTT | |
| SCHEMBL4787314 | 0.81 | BRAF (0.85) | BRAFEGFRABL1BCR | |
| SCHEMBL13878776 | 0.81 | BRAF (0.67) | BRAFEGFRHTT | |
| SCHEMBL4789778 | 0.80 | EGFR (0.88) | BRAFEGFRHTT | |
| SCHEMBL13708169 | 0.79 | BRAF (0.52) | BRAFEGFRABL1 | |
| SCHEMBL13878819 | 0.79 | BRAF (0.64) | BRAFEGFR | |
| SCHEMBL13708182 | 0.79 | CSF1R (0.59) | BRAFABL1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | BRAF 102/4885EGFR 98/4885ABL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.